RenovoRx (RNXT) Other financing activities (2020 - 2025)

RenovoRx has disclosed Other financing activities across 6 years of filings, most recently posting $17000.0 for Q2 2025.

• In Q2 2025, Other financing activities rose 41.67% year-over-year to $17000.0; the TTM figure through Mar 2026 stood at $17000.0 (down 51.43% YoY), while the FY2025 annual figure was $25000.0, down 63.77% from the prior year.
• Other financing activities came in at $17000.0 for Q2 2025 at RenovoRx, up from $8000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $14.5 million in Q3 2021 to a low of -$5.0 million in Q4 2023.
• Average Other financing activities over 5 years is $919187.5, with a median of $10500.0 recorded in 2022.
• The largest YoY upside for Other financing activities was 55388.89% in 2023 against a maximum downside of 166500.0% in 2023.
• Over 5 years, Other financing activities stood at $2000.0 in 2021, then surged by 50.0% to $3000.0 in 2022, then sank by 166500.0% to -$5.0 million in 2023, then soared by 100.3% to $15000.0 in 2024, then grew by 13.33% to $17000.0 in 2025.
• Per Business Quant data, the three most recent Other financing activities figures were $17000.0 in Q2 2025, $8000.0 in Q1 2025, and $15000.0 in Q3 2024.